Login to Your Account

Genentech's Q1 EPS, Avastin Sales Both Above Estimates

By Karen Pihl-Carey

Friday, April 9, 2004
With first-quarter results that significantly surpassed analyst expectations, investors might find themselves shaking their heads or smiling widely - depending on whether or not they bought Genentech Inc.'s stock a year ago when it was running in the mid-$30 range. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription